Other possible causes of primary resistance to anti MET drugs in gastric cancer are i) coamplification of different driver oncogenes, a phenomenon that was recently reported to frequently occur in gastro-esophageal cancer and ii) the extensive heterogeneity in MET gene amplification among distinct tumor lesions within the same patient [55]. Here, MET is linked to neoplasm.